New drug combo shows promise in early cancer trial
NCT ID NCT01334073
First seen May 16, 2026 · Last updated May 25, 2026 · Updated 2 times
Summary
This early-phase study tested a combination of two drugs, axitinib and everolimus, in 19 adults with advanced solid tumors, especially kidney cancer. The main goal was to find the safest dose by monitoring side effects. Participants had already tried other treatments or could not take them. The study was completed and focused on safety, not cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Professeur Alain RAVAUD
Bordeaux, 33000, France
-
Professeur Jean-Pierre DELORD
Toulouse, 31000, France
Conditions
Explore the condition pages connected to this study.